

FIGURE 1

BEST AVAILABLE COPY

FIGURE 2B



SCF IL3





FIGURE 2A



SCF IL3 EPO



BEST AVAILABLE COPY

PV PATIENT




FIGURE 3

BEST AVAILABLE COPY

4 / 11




FIGURE 4

BEST AVAILABLE COPY





FIGURE 5

6 / 11




FIGURE 6B





FIGURE 6A



JAK2 WT

FIGURE 6C

8 / 11




FIGURE 7

9 / 11

sequences for V617F JAK2 of the siRNA #1, 2 and 3

UGGAGUAUGU	UUCUGUGGA	position 11 = siRNA #3
GGAGUAUGU	UUCUGUGGAG	position 10 = siRNA #1
GAGUAUGU	UUCUGUGGAGA	position 9 = siRNA #4



Mutation

FIGURE 8





FIGURE 9

11 / 11



Reduced expression of WT JAK2 by
non-specific JAK2 V617F siRNA
(positive control)

Jak2

FIGURE 10

BEST AVAILABLE COPY